Actio Biosciences
Actio Biosciences develops genetics‑led therapies for rare and common diseases. The company applies human genetic insights and precision medicine approaches to identify drug targets and advance a pipeline including candidates for Charcot‑Marie‑Tooth disease type 2C (TRPV4 inhibitor ABS‑0871) and KCNT1‑related epilepsy (ABS‑1230). It conducts preclinical and Phase 1 studies to evaluate safety, tolerability, and pharmacokinetics for its lead programs. The company also engages in collaboration, licensing, and clinical trial planning to support development and potential expansion into more common indications.
Domain
actiobiosciences.com
Country
United StatesIndustry
BioinformaticsEmployees
11-50
Last Funding
$66.0M
Founded
2020
Tech Stack (11 technologies)
Frequently Asked Questions
What technologies does Actio Biosciences use?+
Actio Biosciences uses 11 technologies including WordPress, core-js, LazySizes.
What industry is Actio Biosciences in?+
Actio Biosciences operates in the Bioinformatics industry.
Where is Actio Biosciences based?+
Actio Biosciences is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026